According to Nova One Advisor, the global personalized medicine biomarkers market size was exhibited at USD 21.95 billion in 2024 and is projected to hit around USD 79.26 billion by 2034, growing at a CAGR of 13.7% during the forecast period 2024 to 2034.
Personalized Medicine Biomarkers Market Key Takeaways:
• The North America personalized medicine biomarkers market dominated the global market and accounted for 52.0% of revenue share in 2024
• The treatment selection segment dominated the market with the largest market share of 50.2% in 2024.
• Early detection/screening is expected to grow at a significant CAGR of 15.8% over the forecast period.
• Oncology dominated the market with the largest share of 36.0% in 2024, driven by the increasing prevalence of cancer worldwide.
• The diabetes segment is the fastest-growing segment and is expected to grow at a CAGR of 17.4% over the forecast period.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report@ https://www.novaoneadvisor.com/report/sample/7571
The growth of the personalized medicine biomarkers market can be attributed to the increasing prevalence of chronic diseases across the globe and the increasing demand for personalized treatment regimes. The increasing emphasis on personalized medicine, which seeks personalized healthcare based on individual characteristics, is further driving the market growth. The increasing emphasis on patient-centric healthcare models is boosting market growth.
The personalized medicine biomarkers market is driven by the growing need for precision medicine in cardiology, oncology, and other therapeutic areas and the increasing prevalence of chronic diseases. The demand for biomarkers that can accurately monitor and detect cancer in children has increased, as diagnostic tools improve. There is an increased focus on understanding patients' unique biological profiles, as healthcare systems move towards more individualized approaches.
In addition, technological advancements play an important role in the personalized medicine biomarkers market. The rising innovations such as molecular imaging, bioinformatics, and next-generation sequencing (NGS) have revolutionized the validation processes and biomarker discovery. These advanced technologies allow for more accurate and early diagnosis and enable the identification of specific biomarkers associated with various cancers.
For example, leading to the discovery of novel genetic mutations that can serve as potential biomarkers, NGS facilitates the comprehensive analysis of cancer genomes. These technological innovations contribute to the development of targeted therapies and enhance the precision of diagnostics, further enhancing the market growth.
Major Trends in the Personalized Medicine Biomarkers Market
• The rising additional advantages provided by biomarkers, which involve the capability to reduce treatment costs, improve patient survival, and detect health conditions in their early stages contributed to propel the market growth.
• Healthcare providers can improve overall patient satisfaction and outcomes, by tailoring medical interventions to individual patients expected to enhance the market growth during the forecast period.
• The increasing use of personalized medicine biomarkers as a major tool for patient matching and screening the right patient with accurate therapy is driving the demand for this equipment.
• The increasing prevalence of unhealthy lifestyle habits, such as physical inactivity, poor dietary choices, and smoking among others are further anticipated to boost the growth of the personalized medicine biomarkers market.
• Clinical studies continuously use biomarkers to improve patient results and their application and rising advances in proteomics and genomics are further anticipated to enhance the market growth.
U.S. Personalized Medicine Biomarkers Market Size and Growth 2024 to 2034
The U.S. Personalized Medicine Biomarkers Market size is exhibited at USD 9.68 billion in 2024 and is projected to be worth around USD 40.90 billion by 2034, growing at a CAGR of 15.5% from 2024 to 2034.
The North America personalized medicine biomarkers market dominated the global market and accounted for 52.0% of revenue share in 2024. The market growth in the region is attributed to the rising funding for biomarkers helped by the presence of key market players operating in the region, high disposable income, and technological advancements. In addition, to maintain dominance over the market, various major players are focusing on developing novel products in the region.
For instance, in February 2022, to categorize patients with microsatellite instability-high solid tumors, Foundation One CDx was approved by the FDA approval as a companion diagnostic for Keytruda.
U.S. Personalized Medicine Biomarkers Market Trends
The U.S. personalized medicine biomarkers market held a significant share of North America market in 2024, driven by advancements in genomics and increased demand for targeted therapies. Rising investments in research, regulatory support for companion diagnostics, and a growing emphasis on precision medicine in oncology and chronic disease management are further propelling market expansion in this sector.
Europe Personalized Medicine Biomarkers Market Trends
The Europe personalized medicine biomarkers market driven by advancements in personalized medicine and intensive research efforts in oncology. Innovations such as next-generation sequencing and proteomics are improving biomarker discovery and diagnostic accuracy, enabling more tailored treatment approaches. European research institutions are increasingly focused on identifying novel biomarkers specific to cancers and other chronic disorders, fostering innovation in personalized medicine. According to the European Society of Cardiology, approximately 45% of individuals over the age of 65 are affected by cardiovascular diseases (CVDs), highlighting the significant health challenges faced by this demographic. In 2022, nearly 4 million people in Europe died from CVDs. This combination of technological advancements and dedicated research initiatives is significantly propelling the growth of the personalized medicine biomarkers market across the region, enhancing the potential for targeted therapies and improved patient outcomes.
The UK personalized medicine biomarkers market is expected to show significant growth driven by increasing research and development investments and enhanced funding for innovative projects. This financial support is facilitating the discovery of novel biomarkers and advancing precision medicine initiatives, leading to improved diagnostics and targeted therapies, ultimately enhancing patient outcomes across the region.
The Germany personalized medicine biomarkers market is experiencing significant growth, largely due to the rising prevalence of chronic disorders such as cancer, diabetes, and cardiovascular diseases. This increasing burden on healthcare systems is driving demand for targeted diagnostics and tailored therapies, fostering advancements in personalized medicine and enhancing patient care in the region.
Asia Pacific Personalized Medicine Biomarkers Market Trends
The Asia Pacific personalized medicine biomarkers market is expected to grow at the fastest CAGR over the forecast period. The growth of the market in the region is owing to growing healthcare reforms in the region aided by improved healthcare infrastructure, a growing population, and an increase in the number of companies entering the market. The Asia Pacific region has a large population and high cancer prevalence. Thus, the usage of screening tests for cancer has increased in the past few years owing to growing government initiatives, such as free screening for breast cancer and increased collaborations for the distribution and supply of these tests.
The China personalized medicine biomarkers market is growing at a lucrative rate. Presence of government funding and initiatives in the region further fuels regional growth. For instance, The Chinese Personal Medicine Initiative which is expected to be funded with USD 9.0 billion by 2030, aims to provide better healthcare provisions mainly for oncology.
Latin America Personalized Medicine Biomarkers Market Trends
The Latin America personalized medicine biomarkers market exhibits high growth potential for the personalized medicine biomarkers market. Driven by improvements in healthcare infrastructure and strong government support. Many countries in the region are investing in modernizing their healthcare systems, which enhances access to advanced diagnostic tools and personalized treatment options. Government initiatives aimed at promoting research and development in personalized medicine are further accelerating market expansion. Additionally, as awareness of the benefits of tailored therapies increases among healthcare providers and patients, demand for biomarkers that facilitate precision medicine is on the rise. These factors collectively contribute to the positive trajectory of the personalized medicine biomarkers market in Latin America.
Middle East and Africa Personalized Medicine Biomarkers Market Trends
The MEA personalized medicine biomarkers market growth driven by the increasing prevalence of chronic disorders, such as diabetes, cardiovascular diseases, and cancer. As healthcare systems in the region focus on improving diagnosis and treatment through personalized medicine, the demand for innovative biomarkers is rising, enhancing patient outcomes.
The Saudi Arabia personalized medicine biomarkers market growth is driving the market, largely supported by government funding aimed at enhancing healthcare innovation. Increased investment in research initiatives and the establishment of advanced healthcare facilities are fostering the development of novel biomarkers, which are essential for improving personalized treatment strategies and patient care in the region.
Immediate Delivery is Available | Get Full Report Access@ https://www.novaoneadvisor.com/report/checkout/7571
Personalized Medicine Biomarkers Market Report Scope
|
Report Attribute |
Details |
|
The market size value in 2025 |
USD 24.96 billion |
|
The revenue forecast in 2034 |
USD 79.26 billion |
|
Growth rate |
CAGR of 13.7% from 2024 to 2034 |
|
Actual data |
2019 - 2023 |
|
Forecast period |
2024 - 2034 |
|
Quantitative units |
Revenue in USD billion/million, and CAGR from 2024 to 2034 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Application, Indication, Region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
U.S.; Canada; Mexico; Germany; France; UK; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
|
Key companies profiled |
Laboratory Corporation of America Holding; Quest Diagnostics Incorporated; Agilent Technologies, Inc.; Genome Medical, Inc.; Coriell Life Sciences; Thermo Fisher Scientific Inc.; NeoGenomics Laboratories; FOUNDATION MEDICINE, INC.; Illumina, Inc.; Guardant Health. |
|
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Precision medicine: Promising future as
AI, biomarkers and technology bolster the field It has been over a decade since Emily
Whitehead was declared cancer-free after the first successful, experimental CAR
T-cell treatment, a moment which marked a huge development in precision
medicine. Since then, the landscape has focused on CAR-T therapies with six of
these now approved. One of the newest movements in the field is with CRISPR
therapies, further progressing the ability of precision medicine to provide
long-term effective treatments for rare and complex diseases. According to nova one advisor , cell
therapies remain the leading drug type by clinical trial count. However, there
has been a notable increase in gene therapies in the past few years. Only 39 gene therapies were marketed by the
end of H1 2023. Despite this, the market is expected to grow drastically over
the next decade, with nova one advisor predicting that gene therapies will
generate nearly $55bn in sales by 2029. At the same time, the cell therapy
market is also expected to surge, with a predicted forecast of over $53bn by
2029, up from nearly $4bn in 2022, according to nova one advisor . Precision medicine trials have always been
oncology-focused due to the mechanism of action (MoA) of most candidates,
targeting and killing T-cells. The field continues to favour oncology however,
other indications, especially rare diseases, are now being investigated to see
how they can utilise precision medicine. Oncology remains the main target for
both cell and gene therapies Better use of biomarkers will further
develop the field One of the biggest advancements in
precision medicine is the use of biomarkers. Biomarker diagnostic tools have
advanced greatly in recent years, with oncology remaining a key area for
biomarker-driven therapy. Consequently, biomarkers will be used to target
subpopulations across cancer types, for example, the identification of specific
mutations in tumour cells. The development of new diagnostics and
discovery of new biomarkers will advance the precision medicine space as
physicians will be better placed to identify targeted treatments for more
indications. Further research into biomarkers and more
advanced diagnostic tools will be required to drive the development of
next-generation precision medicine. Sethi believes that this can be a way to
utilise AI in precision medicine to identify both clinical trial populations
and patient populations post-approval. One advancement is the invention of digital
biomarkers, moving away from the traditional blood biomarker model. NeuraLight,
a startup developing an AI-driven platform that measures eye movements to
diagnose neurological diseases. Personalized Medicine Biomarkers Market Segment
Insights By Application Types The treatment selection segment dominated
the market with the largest market share of 50.2% in 2024. Personalized
medicine biomarkers help choose the most suitable patients for early phase clinical
trials, based on the molecular characteristics of the tumor. The
segment provides data related to the action mechanism of a particular medicine.
The probability of tackling the condition increases, with an enhanced selection
of treatment which drives the demand for personalized medicine biomarkers. In
addition, the major focus of cancer drug development programs has preferred
from the production of non-specific cytotoxic chemotherapies to the production
of targeted therapies as a result of the identification of special mutations
that effectively perform the projection for a given drug. The Early detection/screening is expected
to grow at a significant CAGR of 15.8% over the forecast period. The segment
growth is driven by the increasing need to offer early treatment. The
probability of survival is dependent on the course of treatment, for patients
who display the biomarker linked to a therapy's response. In addition, KRAS is
a biomarker for anti-EGFR monoclonal antibody therapy resistance and a
frequently mutated oncogene in colorectal cancer. Furthermore, the rising
development of novel technologies to aid in the early treatment of several
diseases is further driving the market growth. By Indication Types The Oncology dominated the market with the
largest share of 36.0% in 2024. The oncology segment growth is attributed to
the rising prevalence of cancer globally. Personalized medicine, which tailors’
treatment based on molecular profiles and individual genetics, minimizes
adverse effects and enhances the efficacy of cancer therapies. In addition, the
demand for biomarkers that can predict patient responses to immunotherapies and
targeted therapies is improving overall patient outcomes in oncology and
facilitating earlier detection, thus driving segment growth in the market. • For instance,
cancer cases are projected to rise to 29.5 million by 2040, necessitating more
precise therapeutic and diagnostic approaches, according to the World Health
Organization. • For instance,
there were 18,741,966 cancer cases globally in 2022 according to GLOBOCAN. The
9,175,141 cases were recorded in women, while 9,566,825 cases were reported in
men. The diabetes segment is the fastest-growing
segment and is expected to grow at a CAGR of 17.4% over the forecast period.
The diabetes segment is witnessing significant growth across the market for
personalized medicine biomarkers market, enhanced by the increasing global
prevalence of diabetes. In addition, personalized medicine plays an important
role in diabetes management by optimizing therapeutic strategies and
identifying patients at risk for complications. The demand for personalized
medicine biomarkers that can predict insulin sensitivity, glycemic control, and
other metabolic responses is rising, improving patient outcomes in diabetes
care and fostering advancements in targeted therapies. • For instance,
the global number of individuals living with diabetes is at the forefront and
is anticipated to rise by 46% from 2020 to 2045, while the world’s population
is expected to grow by just 20%, according to the IDF Diabetes Atlas. Related Report Personalized Testing & Supplements
Market- The personalized
testing & supplements market size was exhibited at USD 10.44
billion in 2023 and is projected to hit around USD 44.88 billion by 2033,
growing at a CAGR of 15.7% during the forecast period 2024 to 2033. Global Personalized Retail Nutrition And
Wellness Market- The global personalized
retail nutrition and wellness market size was exhibited at USD 3.65
billion in 2023 and is projected to hit around USD 15.04 billion by 2033,
growing at a CAGR of 15.21% during the forecast period 2024 to 2033. Personalized Medicine Market- The global personalized
medicine market size was valued at USD 530.11 billion in 2023 and is
anticipated to reach around USD 1,176.66 billion by 2033, growing at a CAGR of
8.30% from 2024 to 2033. Personalized Medicine Outsourcing Market- The global personalized
medicine outsourcing market size was valued at USD 102.19 billion in
2023 and is anticipated to reach around USD 323.96 billion by 2033, growing at
a CAGR of 12.23% from 2024 to 2033. U.S. Personalized Nutrition &
Supplements Market- The U.S.
personalized nutrition & supplements market size was valued at USD
6.19 billion in 2023 and is anticipated to reach around USD 28 billion by 2033,
growing at a CAGR of 16.29% from 2024 to 2033. Personalized Medicine Biomarkers Market
Top Companies • Laboratory Corporation of America Holding
• Quest Diagnostics Incorporated • Coriel Life Sciences • Thermo Fisher Scientific
Inc. • Illumina, Inc. Recent Developments • In October 2024, myeloMATCH, a unique
portfolio of biomarker-driven precision medicine clinical trials was launched
by the U.S. National Institutes of Health. This biomarker will test new
treatments for patients with myeloid cancers. • In July 2024, PandaOmics Box, an
AI-powered hardware platform was launched by Insilico for personalized medicine
research and on-premises drug discovery. • In July 2024, a company focused on
proprietary AI and network biology platform solutions to transform patient
care, Scipher Medicine launched a new approach to develop biomarkers following
the publication of the novel, patent-pending framework PRoBeNet (Predictive
Response Biomarkers using Network medicine). Segments Covered in the Report This report forecasts revenue growth at
country levels and provides an analysis of the latest industry trends in each
of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc.
has segmented the personalized medicine biomarkers market By Application • Early Detection/Screening • Diagnosis • Treatment Selection • Monitoring By Indication • Oncology o By Type o Breast Cancer o Lung Cancer o Colon Cancer o Others o By Circulating
Biomarkers o Circulating
Tumor Cells(CTCs) o Circulating
Cell-free DNA(cfDNA) o Extracellular
Vesicles (EVs) o Other
Circulating Biomarkers • Diabetes • Autoimmune Diseases • Cardiology • Others By Regional • North America • Europe • Asia Pacific • Latin America • Middle East and Africa (MEA) Immediate Delivery Available | Buy This
Premium Research https://www.novaoneadvisor.com/report/checkout/7571
USA: +1 804
441 9344 APAC: +61
485 981 310 or +91 87933 22019 Europe: +44
7383 092 044 Email: sales@novaoneadvisor.com Web: https://www.novaoneadvisor.com/
You can place an order or ask any
questions, please feel free to contact at sales@novaoneadvisor.com |
+1 804 441 9344
